Gabelli Funds LLC Sells 2,025 Shares of Baxter International Inc. (NYSE:BAX)

Gabelli Funds LLC trimmed its position in shares of Baxter International Inc. (NYSE:BAX) by 0.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 267,850 shares of the medical instruments supplier’s stock after selling 2,025 shares during the quarter. Gabelli Funds LLC owned 0.05% of Baxter International worth $12,203,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. RFP Financial Group LLC bought a new position in shares of Baxter International during the 2nd quarter valued at $36,000. KB Financial Partners LLC bought a new position in shares of Baxter International during the 1st quarter valued at $81,000. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its holdings in shares of Baxter International by 1,295.4% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,121 shares of the medical instruments supplier’s stock valued at $86,000 after buying an additional 1,969 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Baxter International by 41.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 2,214 shares of the medical instruments supplier’s stock valued at $90,000 after buying an additional 647 shares during the period. Finally, Massmutual Trust Co. FSB ADV lifted its holdings in shares of Baxter International by 50.7% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 2,063 shares of the medical instruments supplier’s stock valued at $94,000 after buying an additional 694 shares during the period. 85.47% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BAX. StockNews.com upgraded Baxter International from a “hold” rating to a “buy” rating in a research note on Monday, November 6th. Deutsche Bank Aktiengesellschaft upped their price objective on Baxter International from $35.00 to $50.00 and gave the stock a “hold” rating in a research note on Tuesday, October 24th. Citigroup reduced their price objective on Baxter International from $45.00 to $41.00 in a research note on Monday, October 2nd. JPMorgan Chase & Co. reduced their price objective on Baxter International from $49.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, October 31st. Finally, Barclays reduced their price objective on Baxter International from $58.00 to $54.00 and set an “overweight” rating for the company in a research note on Monday, July 31st. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $47.25.

Baxter International Trading Up 0.5 %

Shares of Baxter International stock opened at $35.62 on Tuesday. The firm has a market cap of $18.07 billion, a price-to-earnings ratio of 6.98, a PEG ratio of 2.62 and a beta of 0.58. The business has a 50-day moving average price of $35.14 and a 200-day moving average price of $40.59. The company has a quick ratio of 1.48, a current ratio of 1.94 and a debt-to-equity ratio of 1.72. Baxter International Inc. has a twelve month low of $31.01 and a twelve month high of $56.92.

Baxter International Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, January 2nd. Stockholders of record on Friday, December 1st will be given a dividend of $0.29 per share. The ex-dividend date of this dividend is Thursday, November 30th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 3.26%. Baxter International’s payout ratio is 22.75%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.